

Developments in Statistical Evaluation of Clinical Trials

Kees van Montfort • Johan Oud •
Wendimagegn Ghidey
Editors

Developments in Statistical Evaluation of Clinical Trials

 Springer

Editors

Kees van Montfort
Department of Biostatistics
Erasmus Medical Center
Rotterdam
The Netherlands

Johan Oud
Behavioural Science Institute
University of Nijmegen
Nijmegen
The Netherlands

Wendimagegn Ghidey
Department of Hematology
Erasmus Medical Center
Rotterdam
The Netherlands

ISBN 978-3-642-55344-8

ISBN 978-3-642-55345-5 (eBook)

DOI 10.1007/978-3-642-55345-5

Springer Heidelberg New York Dordrecht London

Library of Congress Control Number: 2014951708

© Springer-Verlag Berlin Heidelberg 2014

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher's location, in its current version, and permission for use must always be obtained from Springer. Permissions for use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable to prosecution under the respective Copyright Law.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

While the advice and information in this book are believed to be true and accurate at the date of publication, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Printed on acid-free paper

Springer is part of Springer Science+Business Media (www.springer.com)

Preface

Over the last few decades the role of statistics in the evaluation and interpretation of clinical data has become more and more important. As a result the standards of clinical study design, conduct and interpretation have been advanced. In this book statistical considerations in data analysis as a basis for deriving an accurate clinical interpretation are elaborated.

Most often it is the physician who decides whether to prescribe a specific drug for a specific patient in a specific situation. The decisions of the physicians are largely based on the interpretation of data they have read and heard. This book describes various ways of approaching and interpreting the data that result from a clinical trial study.

The book reemphasizes the essential role that biostatistics plays in clinical trials. The book contains 18 carefully reviewed chapters on recent developments in trials and statistics. The chapters in this book are generally autonomous and may be read in any order. Each chapter is written by one or more experts in the specific approach. Starting from (a) some background information about the specific approach (short history and main publications), the chapter (b) describes the type of research questions the approach is able to answer and the kind of data to be collected, (c) gives the statistical and mathematical explanation of the model(s) used in the analysis of the data, (d) discusses the input and output of the software used in the analysis, and (e) provides one or more examples with typical data sets enabling the readers to apply the programs themselves. The chapters are worked out in a homogeneous style to enhance comparability between the approaches. The data sets and the computer code for the analysis with various softwares are a very important component of the book. They are available upon request (by emailing the authors of the chapters).

Each chapter is self-contained in this edited volume. The chapters are written and reviewed by experts in the specific approach. Although an authored volume could have advantages, because of the rapid changes in the field, an edited book written by people who are in the middle of the latest developments in the specific approach

is preferable. In addition, the authors of the chapters use a shared notation to enable the reader to compare methods more easily.

The book addresses the great majority of researchers in the field of clinical trials. Included are biostatisticians, medical researchers and physicians. It is meant as a reference work for all those actually doing and using research in the field of clinical trials. To reach this vast audience, knowledge of statistics as taught at master degree level in medical and biomedical sciences is required. However, the restricted number of chapters gives each of the chapters the opportunity to go into sufficient details to enable the readers to understand and apply the methods. In addition, the book addresses biostatisticians and physicians, who are professionally dealing with research in the field of clinical trials, to provide standards for state-of-the-art practices. Furthermore, the book offers researchers new ideas about the use of biostatistical analysis in solving their research problems. Finally the book is suitable as obligated literature for courses in clinical trial evaluation given at university medical and epidemiological research schools.

We thank the authors of the chapters for their willingness to contribute to the book, the anonymous reviewers for their expertise and time invested and Springer Publishers for their decision to publish the book in their Statistics book program.

Rotterdam, The Netherlands
Nijmegen, The Netherlands
Rotterdam, The Netherlands

Kees van Montfort
Johan Oud
Wendimagegn Ghidey

Contents

1	Statistical Models and Methods for Incomplete Data in Randomized Clinical Trials	1
	Michael A. McIsaac and Richard J. Cook	
2	Bayesian Decision Theory and the Design and Analysis of Randomized Clinical Trials	29
	Andrew R. Willan	
3	Designing Multi-arm Multi-stage Clinical Studies	51
	Thomas Jaki	
4	Statistical Approaches to Improving Trial Efficiency and Conduct	71
	Janice Pogue, P.J. Devereaux, and Salim Yusuf	
5	Competing Risks and Survival Analysis	85
	Kees van Montfort, Peter Fennema, and Wendimagegn Ghidey	
6	Recent Developments in Group-Sequential Designs	97
	James M.S. Wason	
7	Statistical Inference for Non-inferiority of a Diagnostic Procedure Compared to an Alternative Procedure, Based on the Difference in Correlated Proportions from Multiple Raters	119
	Hiroyuki Saeki and Toshiro Tango	
8	Design and Analysis of Clinical Trial Simulations	139
	Kazuhiko Kuribayashi	
9	Causal Effect Estimation and Dose Adjustment in Exposure-Response Relationship Analysis	153
	Jixian Wang	

10	Different Methods to Analyse the Results of a Randomized Controlled Trial with More Than One Follow-Up Measurement	177
	Jos W.R. Twisk	
11	Statistical Methods for the Assessment of Clinical Relevance	195
	Meinhard Kieser	
12	Statistical Considerations in the Use of Composite Endpoints in Time to Event Analyses	209
	Richard J. Cook and Ker-Ai Lee	
13	Statistical Validation of Surrogate Markers in Clinical Trials	227
	Ariel Alonso, Geert Molenberghs, and Gerard van Breukelen	
14	Biomarker-Based Designs of Phase III Clinical Trials for Personalized Medicine	247
	Shigeyuki Matsui, Takahiro Nonaka, and Yuki Choai	
15	Dose-Finding Methods for Two-Agent Combination Phase I Trials	265
	Akihiro Hirakawa and Shigeyuki Matsui	
16	Multi-state Models Used in Oncology Trials	283
	Birgit Gaschler-Markefski, Karin Schiefele, Julia Hocke, and Frank Fleischer	
17	Review of Designs for Accommodating Patients' or Physicians' Preferences in Randomized Controlled Trials	305
	Afisi S. Ismaila and Stephen D. Walter	
18	Dose Finding Methods in Oncology: From the Maximum Tolerated Dose to the Recommended Phase II Dose	335
	Xavier Paoletti and Adélaïde Doussau	

List of Contributors

Ariel Alonso Department of Methodology and Statistics, Maastricht University, Maastricht, The Netherlands

Gerard van Breukelen Department of Methodology and Statistics, Maastricht University, Maastricht, The Netherlands

Yuki Choai Department of Statistical Science, School of Multidisciplinary Sciences, The Graduate University for Advanced Studies, Tachikawa, Tokyo, Japan

Richard J. Cook Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada

P. J. Devereaux Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada

Adélaïde Doussau USMR, Bordeaux University-Hospital, ISPED Centre INSERM U897-Epidemiologie-Biostatistique, Bordeaux, France

Peter Fennema Advanced Medical Research, Männedorf, Switzerland

Frank Fleischer Department of Biostatistics, Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach, Germany

Birgit Gaschler-Markefski Department of Biostatistics, Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach, Germany

Wendimagegn Ghidey Department of Hematology, Erasmus Medical Center, The Netherlands

Akihiro Hirakawa Center for Advanced Medicine and Clinical Research, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Japan

Julia Hocke Department Biostatistics, Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach, Germany

Afisi S. Ismaila Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada

Thomas Jaki Medical and Pharmaceutical Statistics Research Unit, Department of Mathematics and Statistics, Lancaster University, Lancaster, United Kingdom

Meinhard Kieser Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany

Kazuhiko Kuribayashi Pfizer Japan Inc., Tokyo, Japan

Ker-Ai Lee Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada

Shigeyuki Matsui Department of Biostatistics, Graduate School of Medicine, Nagoya University, Showa-ku, Nagoya, Japan

Michael A. McIsaac Department of Public Health Sciences, Queen's University, Kingston, ON, Canada

Geert Molenberghs I-BioStat, Universiteit Hasselt, Diepenbeek, Belgium
KU Leuven, Leuven, Belgium

Kees van Montfort Department of Biostatistics, Erasmus Medical Center, Rotterdam, The Netherlands

Takahiro Nonaka Pharmaceuticals and Medical Devices Agency, Chiyoda-ku, Tokyo, Japan

Johan H.L. Oud Behavioural Science Institute, Radboud University Nijmegen, Nijmegen, The Netherlands

Xavier Paoletti Department of Biostatistics/INSERM U900, Institut Curie, Paris, France

Janice Pogue Department of Clinical Epidemiology and Biostatistics and Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada

Hiroyuki Saeki FUJIFILM RI Pharma Co. LTD., Chuo-ku, Tokyo, Japan

Karin Schiefele Department of Epidemiology and Medical Biometry, University Ulm, Ulm, Germany

Toshiro Tango Center for Medical Statistics, Minato-ku, Tokyo, Japan

Jos W.R. Twisk Department of Epidemiology and Biostatistics, VU Medical Centre, Amsterdam, The Netherlands

Stephen D. Walter Department of Medicine, McMaster University, Hamilton, ON, Canada

Jixian Wang Novartis Pharma AG, Basel, Switzerland

James M.S. Wason MRC Biostatistics Unit Hub for Trials Methodology Research, Institute of Public Health, Cambridge, United Kingdom

Andrew R. Willan SickKids Research Institute, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada

Salim Yusuf Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada